tyzivumab (TY-008) / Tychan - LARVOL DELTA

Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Tychan Pte Ltd. | N=28 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease